3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase NA
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Other hematologic neoplasm
3
Gastrointestinal
3
Thoracic
2
Lymphoid
2
Gynecologic
2
Classical hematology
2
Plasma cell
1
Other neoplasm
1
Myeloid
1
Genitourinary
1
Dermatologic
1
Conditions
Melanoma
158
Keratosis, Actinic
75
Lymphoma, T-Cell, Cutaneous
36
Skin Neoplasms
27
Mycosis Fungoides
27
Lymphoma, Non-Hodgkin
25
Lymphoma, Mantle-Cell
25
Lymphoma, Large-Cell, Immunoblastic
25
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, Follicular
25
Leukemia, Lymphocytic, Chronic, B-Cell
25
Hodgkin Disease
25
Sezary Syndrome
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Lymphoma, B-Cell, Marginal Zone
24
Burkitt Lymphoma
24
Neoplasms
22
Carcinoma, Basal Cell
22
Neoplasm Metastasis
20
Multiple Myeloma
20
Leukemia, Myeloid, Chronic-Phase
20
Leukemia, Myeloid, Accelerated Phase
20
Leukemia, Hairy Cell
20
Leukemia, Myeloid, Acute
19
Blast Crisis
19
Primary Myelofibrosis
18
Lymphoma
18
Uveal Melanoma
17
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, Large-Cell, Anaplastic
17
Interventions
peginterferon alfa-2b
1
Introns
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Drug-Related Side Effects and Adverse Reactions
×
Dermatologic
×
Clear all
NCT00221702
2010-10-13
EADO
University Hospital, Bordeaux
Phase 3
Completed
898 enrolled